市場調査レポート

カンナビノイド市場の今後の可能性

CANNABINOIDS: A POTENTIAL BLOCKBUSTER?

発行 Visiongain Ltd 商品コード 30157
出版日 ページ情報 英文 150+ pages, 29 tables, 17 graphs & charts
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
カンナビノイド市場の今後の可能性 CANNABINOIDS: A POTENTIAL BLOCKBUSTER?
出版日: 2005年02月28日 ページ情報: 英文 150+ pages, 29 tables, 17 graphs & charts

当商品の販売は、2011年07月19日を持ちまして終了しました。

概要

数多くの議論を呼びながらも拡大し続けているカンナビノイド市場で展開されている商品は Unimed Pharmaceuticals社の Marinol(マリノール)と Cambridge Laboratories によって販売されている Nabilone(ナビロン)の2種類のみです。

製薬及び通信産業においての市場調査を専門にしております英国の調査会社 Visiongain(本社:英国ロンドン)では、カンナビノイド製品の今後の可能性に関する調査報告書 "Cannabinoids: A Potential Blockbuster?" を発行いたしました。

当報告書では、カンナビノイド製品に関する詳細な分析、潜在市場、世界的な市場規模と今後5年にわたる展望、カンナビノイド製品がブロックバスター薬となる可能性とその時期、規制課題や社会的問題、企業が直面する問題などについて、図表と併せて、概略下記の構成で取り上げております。

第1章 エグゼクティブサマリー

第2章 カンナビノイドの概要

  • カンナビノイド治療の歴史的背景
  • カンナビノイドの概要
  • 大麻とカンナビノイドの違い
  • カンナビノイド受容体の概要
  • Marinol、Nabilone、Sativex
  • 治療におけるカンナビノイドの可能性
  • カンナビノイドに関する疑問

第3章 カンナビノイドの潜在的治療

  • 治療におけるカンナビノイドの価値
  • Marinol と Nabilone
  • カンナビノイドの潜在的臨床利用概要
  • オピオイドの代替となるか
  • 急性疼痛
  • 術後急性疼痛
  • 慢性疼痛
  • 慢性良性疼痛
  • 神経因性疼痛
  • 片頭痛
  • カンナビノイドと疼痛
  • カンナビノイドと癌関連拒食症
  • カンナビノイドと多発性硬化症
  • カンナビノイドと行動障害
  • ジストニア
  • ハンチントン病
  • パーキンソン病
  • トゥレット症候群
  • カンナビノイドと行動障害の今後
  • カンナビノイドとアルツハイマー病
  • カンナビノイドとてんかん
  • カンナビノイドと関節リウマチ
  • カンナビノイドと緑内障

第4章 世界のカンナビノイド市場

  • 現在のカンナビノイド市場の概要
  • Unimed Pharmaceuticals 社
  • カンナビノイド治療の標準薬としてのMarinol
  • エイズ消耗症患者の拡大によって増加するMarinol の患者人口
  • エイズ消耗症患者人口と並ぶアルツハイマー患者人口
  • Marinol の売上の爆発的な拡大
  • 世界の Marinol 市場
  • Marinol 市場の影響因子
  • Marinol とカンナビノイドのコスト比較
  • 欧州市場における Nabilone の支配
  • 2005 年に 2000 万米ドル規模に達するNabilone の売上
  • Nabilone の収益拡大に向けた取り組み
  • THC Pharma と Delta 9 Pharma
  • 多種多様なカンナビノイドの潜在市場
  • 市場の潜在規模
  • Sativex MS の収益予測(2005-2010)
  • Acomplia AntiObesity の収益予測
  • 業界代表者調査
  • GW Pharmaceuticals 社の見解

第5章 パイプライン製品

  • 1999年代とは大幅に違うパイプライン
  • 大手医薬品会社の大きな関心
  • GW Pharmaceuticals 社の広範囲にわたるパイプラインなど

第6章 カンナビノイド製造会社

  • 会社概要
  • GW Pharmaceuticals
  • Bayer Healthcare
  • Pharmos
  • Yissun Research Development Co.
  • MakScientific/Endo Pharmaceuticals
  • BMS
  • Solvay Pharma

第7章 規制課題と認可薬品

  • 米国
  • 英国
  • 日本
  • フランス
  • ドイツ
  • イタリア

第8章 総論

目次

Abstract

Only two products are available on this controversial yet growing market: Marinol from Unimed Pharmaceuticals and Nabilone marketed by Cambridge Laboratories. However coming soon is the worlds first whole-cannabis derived product - Sativex. This market is growing and you need to know how to take advantage of it - NOW.

The approval of Sativex is imminent. Developed by GW Pharmaceuticals, Sativex is expected to transform the market. The profile of the market will increase further by the expected mid-2006 launch of Acomplia by Sanofi-Aventis for obesity. Will a cannabinoid become the leading product for obesity? Find out in this report.

Visiongain says that the market has already grown 6.3% from 2004s revenues and growth of the market will continue over the forecast period 2005-2010. Visiongain examines two potential markets: 1) if no comers arrive and 2)the potential value following launch of the key future products.

Five key questions this report answers are:

  • Is their a potentially large enough market for cannabinoids
  • Which therapeutic areas are most likely to be responsive to cannabinoid products
  • What is the global cannabinoid market value of today and over the next 5 years?
  • How will the cannabinoid market gain blockbuster status and when?
  • How do you overcome the regulatory and social issues medicinal cannabis use in the 7 major markets?

The report provides in-depth market analysis for current and potential products. This is the leading report in its field and cannot be ignored. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research. The study also assesses the challenges faced by potential cannabinoid companies.

Table of Contents

Chapter 1: Executive Summary of Cannabinoids: A Potential Blockbuster?

  • 1.1 Introduction to the Cannabinoids Market
  • 1.2 Cannabinoid Potential Therapeutic Areas
  • 1.3 GW Pharmaceuticals: The Cannabinoid Company
  • 1.4 Overview of Cannabinoids: A Potential Blockbuster?

Chapter 2: Introduction to Cannabinoids

  • 2.1 A Historical Background to Cannabinoid Therapies
  • 2.2 An Overview of Cannabinoids
    • 2.2.1 Herbal Cannabinoids
    • 2.2.2 Endogenous Cannabinoids
    • 2.2.3 Synthetic Cannabinoids
  • 2.3 How do Cannabinoids Differ to Cannabis?
  • 2.4 An Overview of Cannabinoid Receptors
  • 2.5 Marinol, Nabilone & Sativex: The 3 Medicinal Cannabinoids of Importance
  • 2.6 The Therapeutic Potential of Cannabinoids
  • 2.7 Major Questions Regarding Cannabinoids
    • 2.7.1 Are They Safe?
    • 2.7.2 What Routes of Administration Will be Used for Therapeutics?

Chapter 3: Potential Cannabinoid Therapies

  • 3.1 Cannabinoids of Therapeutic Value
  • 3.2 Marinol and Nabilone: The Only 2 Cannabinoid Drugs on the Global Market
  • 3.3 The Potential Clinical Uses of Cannabinoids Overview
  • 3.4 Cannabinoids and Pain: An Alternative to Opioids?
  • 3.5 Experimentally Induced Acute Pain
  • 3.6 Post Surgical Acute Pain
  • 3.7 Chronic Pain
  • 3.8 Chronic Non-malignant Pain
  • 3.9 Neuropathic Pain
  • 3.10 Migraine
  • 3.11 Cannabinoids and Pain: A Lucrative Market to R&D?
  • 3.12 Cannabinoids and Cancer-Associated Cachexia/Anorexia: Prospects Look Promising
  • 3.13 Cannabinoids and Multiple Sclerosis: The Most Likely Therapeutic Use
  • 3.14 Cannabinoids and Movement Disorders: The Good and Bad
  • 3.15 Dystonia
  • 3.16 Huntingtons Disease
  • 3.17 Parkinsons Disease
  • 3.18 Tourettes Syndrome
  • 3.19 Cannabinoids and Movement Disorders: The Future
  • 3.20 Cannabinoids and Alzheimers Disease: A High Potential
  • 3.21 Cannabinoids and Epilepsy: No Trials Performed, Yet
  • 3.22 Cannabinoids and Rheumatoid Arthritis: A Possible Use
  • 3.23 Cannabinoids and Glaucoma: Temporary Relief Found Cannabinoids and Cancer: A New Hope
    • Cannabinoids and Asthma: Numerous Studies Performed Cannabinoids and
    • Chrons Disease/Ulcerative Colitis: Experimental Data Looks Good
    • Cannabinoids and Depression: Future Looks Good
    • Cannabinoids and Obstetrics/Gynaecology: Centuries Old Remedies May Hold Potential
    • Cannabinoids and Drug Withdrawal: A New High?
    • Cannabinoids and Intractable Breathlessness: A Rare Answer to an Unknown Disease?
    • Cannabinoids and Traumatic Brain Injury: Prospects Injured
    • Cannabinoids and Obesity: A Large Potential
    • Visiongains Perspective of Cannabinoid Therapeutics

Chapter 4: The Worldwide Cannabinoids Market: Current Cannabinoids and Potential Products

  • 4.1 Overview of Todays Global Cannabinoids Market: A Potential Blockbuster?
  • 4.2 Unimed Pharmaceuticals Inc Markets the Leading Cannabinoid Product Marinol
  • 4.3 Marinol is the Standard for New Cannabinoid Therapies
  • 4.4 Marinols Patient Population is Driven by AIDS Wasting
  • 4.5 Alzheimers Disease Set to Compete With AIDS Wasting Patient Population
  • 4.6 Marinol Revenues Boosted by Market Exclusivity and Approval in Various International Markets
  • 4.7 Global Marinol Market: 2004 Revenues Drop Due to Unimed Subsidiaries Distribution Contract Renegotiation
  • 4.8 Market Drivers of Marinol
  • 4.9 Market Restraints of Marinol
  • 4.10 Added Indications of Marinol Will Aid Market Revenues
  • 4.11 Unimed and Nektar Therapeutics Phase I Study of Metered Dose Inhaler (MDI) Holds Promise
  • 4.12 Cost of Marinol vs Cannabis
  • 4.13 Nabilones European Market Dominance
  • 4.14 Nabilones Sales Will Approach the $20 Million Mark in 2005
  • 4.15 Cambridge Labs Must Act Now to Maximise Nabilones Profits
  • 4.16 THC Pharma and Delta 9 Pharma Compete to Supply Germany with Dronabinol (Delta-9- Tetrahydrocannabinol)
  • 4.17 Total Global Cannabinoid Market Worth Almost $200 Million by 2010
  • 4.18 The Potential Therapeutic Market for Cannabinoids is Diverse
  • 4.19 Market Prospects for Cannabinoids Will be Decided by Sativex and Acomplia
  • 4.20 GW Pharmaceuticals Spokesperson: "We are Commencing Sativex Approval Activities in the US in 2005"
  • 4.21 Dexanabinols Traumatic Brain Injury Phase III Results Will Limit Cannabinoid Market Value
  • 4.22 Potential Value of the Cannabinoid Market
  • 4.23 Sativex MS Revenue Forecast: 2005-2010
  • 4.24 Acomplia AntiObesity Revenue Forecast: 2006-2010
  • 4.25 Cannabinoids Potential to Gain Blockbuster Status: Visiongains Perspective
  • 4.26 Will Cannabinoids Achieve Blockbuster Status? A Survey of Industry Representatives
  • 4.27 GW Pharmaceuticals Perspective on Cannabinoids Achieving Blockbuster Status

Chapter 5: Pipeline Cannabinoid Products

  • 5.1 Impressive Cannabinoids Pipeline 2005 is a Far-Cry From That of 1999s
  • 5.2 Growing Interest of Big Pharma in Cannabinoid R&D
  • 5.3 GW Pharmaceuticals Product Pipeline is Extensive
  • 5.4 UK MS Spasticity Status Application of Sativex Rests With MHRA
  • 5.5 Future GW Approval Applications
  • 5.6 Sanofi-Aventis Anti Obesity /Anti Smoking Drug Acomplia is a Potential Blockbuster
  • 5.7 Pharmos "Most Unlikely" to Develop Lead Candidate Dexanabinol Following Disappointing Phase III Traumatic Brain Injury Results
  • 5.8 Atlantic Technology Venture Inc. Commence Phase II Trials for CT-3
  • 5.9 Yissum Drive Cannabinoid Market Progress with Collaborations and Research Efforts
  • 5.10 Pfizers Four CB1 Candidates
  • 5.11 Norvartis Interest in Cannabinoid Agonists for Pain Control
  • 5.12 Novel Selective CB2 Agonists from MakScientific/Endo Pharmaceuticals Inc
  • 5.13 BMS and Solvay Pharmas SLV319 Compound

Chapter 6: Cannabinoid Companies

  • 6.1 Introduction to Cannabinoid Companies
  • 6.2 GW Pharmaceuticals: The Innovative Leading Cannabinoids Company
  • 6.3 GWs Advance Delivery System (ADS) Receives AiM Stock Exchange Award
  • 6.4 Bayer HealthCare & GW in $41 Million Marketing Agreement
  • 6.5 The Israelin Company Pharmos, Dexanabinol and Its Cannabinoid Library
  • 6.6 $50 million for Yissum Research Development Co. from Dexanabinol Agreement Now Under Question
  • 6.7 MakScientific/Endo Pharmaceuticals Inc. and CB2 Agonists
  • 6.8 BMS and Solvay Pharma in AntiObesity Cannabinoid Development and Commercialisation Agreement

Chapter 7: Regulatory Issues of Cannabinoids and Medically Approved Cannabis

  • 7.1 The Politics of Therapeutic Cannabinoid and Cannabis Use: An Introduction
  • 7.2 The US: Two FDA Programmes Aid Cannabinoid Drug Development
  • 7.3 The DEA Rescheduling of Marinol to Schedule III Increases Availability for Patients
  • 7.4 Cannabis Remains under Schedule I of the US 1971Convention on Psychotropic Substances
  • 7.5 Medical Cannabis Now Legal in Eleven US States
  • 7.6 Medical Cannabis Compassion Clubs in the US Growing in Popularity
  • 7.7 New Cannabinoids and Scheduling Regulations in the U.S: Will They Be Subject to Scheduling?
  • 7.8 The UK and Cannabinoids: Schedule I Classification of Misuse of Drugs Act 1971-No Therapeutic Value
  • 7.9 Dronabinol Rescheduled to Schedule II by UK Government
  • 7.10 New Cannabinoid Therapeutics: UK Government Willing to Permit Introduction
  • 7.11 Home Office License Required to Research Cannabinoids in UK
  • 7.12 The House of Lords Science & Technology Committee Reports Back Cannabinoids
  • 7.13 Abstract from The House of Lords Science & Technology Committees Cannabis: The Scientific and Medical Evidence Report
  • 7.14 Japans Cannabis Control Act 1948 Illegalises Medicinal Cannabis and Cannabinoid Research
  • 7.15 France and Cannabinoids: List IV of Decree Law 1990
  • 7.16 French Medics Allowed To Prescribe Cannabinoids Under Temporary Use Authorisations
  • 7.17 Germany and Cannabinoids: Schedule II of the Narcotics Act 1996
  • 7.18 German Federal Government Breaks Its Promise on Medical Cannabis
  • 7.19 German Administrative Court Rejects Law Suits Against the Federal Institute for Pharmaceuticals and Medical Products
  • 7.20 Italy and Cannabinoids: List IV of Decree Law 1992
  • 7.21 Four Italian Regions Request Medicinal Cannabis and Its Derivatives Approval in 2002
    • Italian Judge Forces Italys NHS to Supply Cannabinoids
    • Italians Restricted Supplies of Nabilone and Marinol
    • Spain: No specific Legal Definition of Cannabinoids
    • Spanish Health Minister Announces Intention of Medical Cannabis Extract Availability

Chapter 8: Conclusion to Cannabinoids: A Potential Blockbuster?

  • Conclusion

Tables

  • Table 1.1: Current Cannabinoid Pharmaceuticals Available on the World Market, 2005
  • Table 1.2 Marinol and Nabilone Indications and Approval Dates
  • Table 1.3: Potential Cannabinoid Therapeutic Areas
  • Table 2.1: The Major Cannabinoids in Cannabis
  • Table 2.2: Properties of the Major Cannabinoids Found in Cannabis
  • Table 2.3: Synthetic Cannabinoids and Their Characteristics
  • Table 2.4: Potential Therapeutic Areas of Cannabinoid Therapies
  • Table 2.5: Acute and Chronic Adverse Effects of THC
  • Table 3.1: Potential Diseases All Cannabinoids May Treat, 2005
  • Table 3.2: Globally Marketed Cannabinoids, 2005
  • Table 3.3: Cannabinoid Clinical Trial Outcomes of Various Diseases
  • Table 3.4: Disease Background of Cannabinoid Therapeutic Uses
  • Table 3.5: The Potential Circumstances of Cannabinoid Use in Pain Control
  • Table 3.6: Neuropathic Pain Disorders
  • Table 3.7: Target Patients for Cannabinoid Pain Relief
  • Table 3.8: Visiongains Prespective of the Therapeutic Potential of Cannabinoids by Disease, 2005
  • Table 4.1: Marinol Global Availability, 2005
  • Table 4.2: Total Global Market Revenue Forecast of Marinol ($m), 2002- 2010
  • Table 4.3: Countries where Nabilone is Marketed by Cambridge Labs Distribution Partners
  • Table 4.4: Total Global Market Revenue Forecast of Nabilone ($m), 2002-2010
  • Table 4.5: THC Pharma GmbH Cannabinoid Catalogue Products, 2005
  • Table 4.6: Total Global Market Revenue Forecast of Cannabinoids (Marinol, Nabilone and Dronabinol Combined Sales), $m, 2002- 2010
  • Table 4.7:Sativex Combined Canadian, UK & US MS Market Revenue Forecast ($m), 2005-2010
  • Table 4.8: Multiple Sclerosis Market Leading Therapeuitcs, 2003
  • Table 4.9: Acomplia AntiObesity Market Revenue Forecast ($m), 2006-2010
  • Table 5.1: Cannabinoids Pipeline, 2005
  • Table 5.2: Pfizer CB1 Candidates in R&D, 2005
  • Table 7.1: Schedule III Benefits of Marinol Compared to Schedule II
  • Table 7.2: 11 US States That Have Legalised Medical Use of Cannabis

Graphs

  • Graph 4.1: Total Global Market Revenue Forecast of Marinol ($m), 2002- 2010
  • Graph 4.2: Total Global Marinol Market Revenue Change Forecast (%), 2003-2010
  • Graph 4.3: Total Global Market Revenue Forecast of Nabilone ($m), 2002- 2010
  • Graph 4.4: Total Global Nabilone Market Revenue Change Forecast (%), 2003-2010
  • Graph 4.5: Total Global Market Revenue Forecast of Cannabinoids (Marinol, Nabilone and Dronabinol Combined Sales), $m, 2002- 2010
  • Graph 4.6: Total Global Market of Cannabinoids (Marinol, Nabilone and Dronabinol Combined Sales), Revenue Change Forecast (%), 2003-2010
  • Graph 4.7: Sativex Combined Canadian, UK & US MS Market Revenue Forecast ($m), 2005-2010
  • Graph 4.8: Sativex Combined Canadian, UK & US MS Market Growth Forecast (%), 2006-2010
  • Graph 4.9: Acomplia AntiObesity Market Revenue Forecast ($m), 2006- 2010
  • Graph 4.10: Acomplia AntiObesity Market Growth Forecast (%), 2007- 2010

Charts

  • Chart 2.1: Chemical Structures of the Major Cannabinoids
  • Chart 4.1: Marinol Patient Population, 2003
  • Chart 4.2: Marinol Patient Population, 2010
  • Chart 4.3: Cambridge Labs Distribution Network, 2005
  • Chart 4.4: Survey Results: Will New Cannabinoid Drugs Achieve Blockbuster Status?
  • Chart 5.1: GW Pharmaceuticals Product Pipeline, 2005
Back to Top